Skip to content

Welcome to Discover Pharma! Today is : November 9, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Clinical & Regulatory,Digital & Data,Medical devices,Therapeutic Areas

    Neuraxpharm and mjn-neuro plan launch of digital solution for early detection of epileptic seizures

    Neuraxpharm and mjn-neuro are preparing to launch a digital health [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Manufacturing & Supply Chain

    eXmoor and UCL partner to accelerate academic cell and gene therapy programmes

    eXmoor Pharma has formed a strategic collaboration with University College [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Opinion & Events

    Pistoia Alliance warns of scientific content crisis limiting accuracy of AI in life sciences R&D

    The Pistoia Alliance has reported new findings pointing to a [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    CytoAgents to present new CTO1681 clinical safety data at ASH annual meeting

    CytoAgents will present new clinical safety data for CTO1681 at [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    €1 million investment for BiPER Therapeutics to launch BPR001-615 BiP inhibitor trial

    BiPER Therapeutics has raised €1 million ($1.16M) to support the [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    One-carbon Therapeutics secures SEK 153 million (€13.9 million) to expand Odin trial

    One-carbon Therapeutics has secured SEK 153 million (€13.9 million) in [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    EMA grants orphan drug designation to Kedrion treatment for congenital aceruloplasminemia

    Kedrion has received orphan drug designation from the European Medicines [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    CNS Pharmaceuticals announces primary analysis of Berubicin in second line treatment of glioblastoma multiforme

    CNS Pharmaceuticals has reported the primary analysis of its clinical [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Opinion & Events

    myTomorrows details methodology and adoption of its AI clinical trial pre-screening tool

    myTomorrows has shared new details on the methodology behind its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Flagship Pioneering signs new agreements with ProFound Therapeutics and Quotient Therapeutics with GSK collaboration

    Flagship Pioneering has announced that ProFound Therapeutics and Quotient Therapeutics [...]

    May 5, 2026
Previous434445Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
  • CellProthera and Alfresa sign MOU for ProtheraCytes Phase 3 trial in Japan
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top